Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cizutamig in Systemic Sclerosis
NCT07158996Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of cizutamig in systemic sclerosis (SSc), sponsored by Ruijin Hospital. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 52 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
cizutamig
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07158996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158996.